Literature DB >> 11197168

Reduced proteolysis of surfactant protein A and changes of the bronchoalveolar lavage fluid proteome by inhaled alpha 1-protease inhibitor in cystic fibrosis.

M Griese1, C von Bredow, P Birrer.   

Abstract

In cystic fibrosis (CF), the chronic neutrophilic inflammation of the airways results in proteolytic degradation of lung tissue early in the course of the disease. Inhalation of alpha 1-protease inhibitor (alpha 1-PI) may restore the protease-antiprotease imbalance and thus lead to less tissue damage. To monitor its impacts on bronchoalveolar lavage (BAL) fluid protein pattern (proteome) and on surfactant protein A (SP-A), eight young adults with CF inhaled 100 mg of alpha 1-PI twice daily over eight weeks. BAL fluids were obtained before and after inhalation. Total protein, the number and amount of proteins with a molecular mass < 20 kDa were reduced compared to pretreatment values. Degradation products of SP-A were shown by immunoblotting, being reduced after alpha 1-PI treatment. This pilot study demonstrates that inhalation of alpha 1-PI is associated with biochemical changes consistent with reduced proteolysis. The display of the BAL proteome by two-dimensional electrophoresis may be helpful to quantify the overall molecular changes associated with proteolytic or other lung injuries and offers the possibility to monitor directly therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11197168     DOI: 10.1002/1522-2683(200101)22:1<165::AID-ELPS165>3.0.CO;2-H

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  7 in total

1.  Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis.

Authors:  Amit Gaggar; Junliang Chen; James F Chmiel; Henry L Dorkin; Patrick A Flume; Rhonda Griffin; David Nichols; Scott H Donaldson
Journal:  J Cyst Fibros       Date:  2015-08-28       Impact factor: 5.482

2.  Proteolysis of surfactant protein D by cystic fibrosis relevant proteases.

Authors:  C von Bredow; A Wiesener; M Griese
Journal:  Lung       Date:  2003       Impact factor: 2.584

3.  Linkage of neutrophil serine proteases and decreased surfactant protein-A (SP-A) levels in inflammatory lung disease.

Authors:  F Rubio; J Cooley; F J Accurso; E Remold-O'Donnell
Journal:  Thorax       Date:  2004-04       Impact factor: 9.139

4.  Surfactant protein a in cystic fibrosis: supratrimeric structure and pulmonary outcome.

Authors:  Matthias Griese; Stephanie Heinrich; Felix Ratjen; Michael Kabesch; Karl Paul; Manfred Ballmann; Ernst Rietschel; Matthias Kappler
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

5.  Protein biomarkers in cystic fibrosis research: where next?

Authors:  Sally H Pattison; J Stuart Elborn
Journal:  Genome Med       Date:  2010-12-16       Impact factor: 11.117

6.  SP-A binds alpha1-antitrypsin in vitro and reduces the association rate constant for neutrophil elastase.

Authors:  Marina Gorrini; Anna Lupi; Paolo Iadarola; Conceição Dos Santos; Paola Rognoni; Daniele Dalzoppo; Natalia Carrabino; Ernesto Pozzi; Aldo Baritussio; Maurizio Luisetti
Journal:  Respir Res       Date:  2005-12-13

Review 7.  Lung deposition of inhaled alpha-1-proteinase inhibitor (alpha 1-PI) - problems and experience of alpha1-PI inhalation therapy in patients with hereditary alpha1-PI deficiency and cystic fibrosis.

Authors:  R Siekmeier
Journal:  Eur J Med Res       Date:  2010-11-04       Impact factor: 2.175

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.